June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Switching to aflibercept from ranibizumab in choroidal neovascularization related to angioid streaks: a multicenter real life study
Author Affiliations & Notes
  • Rim Sekfali
    Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
  • gerard mimoun
    Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
    Centre Ophtalmologique d'Imagerie de l'Ecole miliataire, Paris, France
  • Vittorio Capuano
    Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
  • Salomon Y Cohen
    Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
    Centre d'Imagerie et de Laser, Paris, France
  • Camille JUNG
    Centre de Recherche Clinique- Centre de Ressources Biologiques, Hôpital Intercommunal de Créteil, Créteil, France
  • OUBRAHAM-MEBROUKINE Hassiba
    Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
    Centre Ophtalmologique OPHTA45, Montargis, France
  • Giuseppe Querques
    Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
    Departement of ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute, Milan, Italy
  • Eric H SOUIED
    Department of Ophthalmology, Centre Hospitalier Intercommunal de Créteil, Créteil, France
  • Footnotes
    Commercial Relationships   Rim Sekfali, None; gerard mimoun, None; Vittorio Capuano, None; Salomon Cohen, Alcon (C), Allergan (C), Bayer (C), Novartis (C), Thea (C); Camille JUNG, None; OUBRAHAM-MEBROUKINE Hassiba, None; Giuseppe Querques, Allergan (C), Almeria sciences (C), Bausch and Lomb (C), Bayer (C), Heidelberg (C), Novartis (C), Zeiss (C); Eric H SOUIED, Allergan (C), Bayer (C), Novartis (C), Thea (C)
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 2308. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Rim Sekfali, gerard mimoun, Vittorio Capuano, Salomon Y Cohen, Camille JUNG, OUBRAHAM-MEBROUKINE Hassiba, Giuseppe Querques, Eric H SOUIED; Switching to aflibercept from ranibizumab in choroidal neovascularization related to angioid streaks: a multicenter real life study. Invest. Ophthalmol. Vis. Sci. 2017;58(8):2308.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy and the safety of Pro Re Nata (PRN) intravitreal aflibercept (Eylea; VEGF trap-Eye, Regeneron, Tarrytown and Bayer HealthCare, Berlin, Germany) in patients with refractory or recurrent choroidal neovascularization (CNV) secondary to angioid streaks (AS), previously treated by ranibizumab (Lucentis, Novartis Pharma SAS, Huningue, France; 0.5 mg in 0.05 m ).

Methods : Retrospective, multicenter study (n=3). Complete ophthalmic examination, best corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICGA), central macular thickness (CMT) on spectral domain optical coherence tomography (SD-OCT), were collected. Patients were recorded into “refractory” (persistent exudation despite six monthly injections of ranibizumab) and “recurrent” groups (exudation suppressed, but requiring frequent injections with at least two recurrences during the last year before the switch).

Results : Twenty eyes of 16 patients (10 female, 67.3 ± 11.7 years old) were included. Mean follow up was 28.4 ± 8,7 months (range 13-41 months). Mean BVCA at baseline was 0.25 ± 0.33 logMAR and 0.35 ± 0.45 log MAR at the last visit (p 0.17). CMT was 321.8 ± 169.21 µm at baseline and 251.5 ± 63.34 µm at last follow up (p 0.067). Mean number of intravitreal injections of aflibercept was 12.27 ± 6.03. Four eyes were classified as “refractory” and 16 as “recurrent”. No adverse effect was observed.

Conclusions : Switching patients with CNV secondary to AS to aflibercept in a PRN schedule provided a stabilized vision and improved anatomic outcomes.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×